Results pending
Duloxetine: improve symptoms or function in MS (type not specified)
Trial timeline
Trial start year. Dot size reflects participants where reported. Only trials that count towards the status are shown.
MS (type not specified) · Pain, mood, cognition and other symptoms
Trials have finished, but some results have not been read yet. There is no verdict until they are, because one unread trial can change the answer.
- Trials
- 3
- Running now
- 0
- Controlled phase 2/3 trials
- 3
- People in controlled trials
- 515
Deciding trials (phase 3): 1 met, 0 did not.
Other linked trials: 2
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2008 · Placebo-controlled · MSFT-NCT00755807
Phase 3 · 2008 · Placebo-controlled · MSFT-2008-002560-34
Phase 2/3 · 2007 · Placebo-controlled · MSFT-NCT00457730
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as Results pending
Related hypotheses
- Pain, mood, cognition and other symptoms: improve symptoms or function in MS (type not specified)
- Donepezil: improve symptoms or function in MS (type not specified)
- Escitalopram: improve symptoms or function in MS (type not specified)
- Gabapentin: improve symptoms or function in MS (type not specified)
- Ketamine: improve symptoms or function in MS (type not specified)
- Lidocaine: improve symptoms or function in MS (type not specified)
- Pregabalin: improve symptoms or function in MS (type not specified)
- Rivastigmine: improve symptoms or function in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error